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From the Authors:
Professor Tasker queries whether patients undergoing
brainstem death testing could bias the association between
exposure to hyperoxemia and mortality in our recent study
(1). In our database, these patients represent a tiny fraction
of patients evaluated. For the Days 1, 3, 5, and 7 cohorts,
there were only 33 (0.1%), 14 (0.1%), 9 (0.1%), and 6 (0.1%)
patients, respectively, in whom there was semantic labeling
for death confirmed using neurological criteria. Owing to
these low numbers, we did not attempt to stratify by this
variable. This is likely to be a small underestimate of
patients exposed to apnea testing, because this label refers
only to patients who met full criteria rather than to patients
who underwent brainstem death testing itself, though it is
standard practice in the United Kingdom not to proceed
with testing unless there is good evidence that the result is
likely to be positive. A sensitivity analysis, however,
confirms that our original findings are robust even after
exclusion of these patients.
We respectfully disagree that the study implies an “all-or-
nothing” effect. The Royston method for evaluating exposures
with a spike at zero is designed to introduce a discontinuity
in a continuous variable at zero. Both indicator and dose
components must be considered simultaneously. By analogy
to cigarette exposure, this would be akin to suggesting that
smoking is associated with harm, but we are unclear
whether smoking 20 cigarettes per day is worse than
smoking 10. The statistical power to demonstrate the dose-
independent effect is much higher than the dose-dependent
effect.
L’Her and Lellouche request summary distribution
measures of PaO2. Concerning the study variable of interest
(i.e., “hyperoxemia dose,” samples with PaO2 >13.3 kPa), the
median was 15.8 kPa, and the 5%, 25%, 75%, and 95%
centiles were 13.5, 14.3, 18.9, and 30.5 kPa, respectively. This
is a right-skewed distribution, as one would expect after
censoring values ,13.3 kPa. Regardless, we challenge their
assertion that “[i]f the range of PaO2 values is too narrow, no
dose–effect relationship can be established.” The effect of
interest was cumulative exposure, so even minor deviations of
the underlying PaO2 would thus aggregate and become
apparent over time. Notwithstanding this, there was good
variability in the raw data that informed the creation of the
“hyperoxemia dose” variable.
Our approach was clear in that we were trying to create an
unambiguous definition of oxygen excess rather than attempting
to establish an optimal level for PaO2. The paper by Helmerhorst
and colleagues (2) that L’Her and Lellouche cited did not, in
our view, account for inherent confounding from treatment–
physiology interactions; the optimal PaO2 they reported should
be viewed with a degree of healthy skepticism. We believe
that questions regarding optimal PaO2 and the importance of
balancing this against prevention of significant hypoxemia
remain unanswered. Although there is mounting evidence of the
harm associated with excess oxygen exposure, there remains a
lack of strong causal evidence. We advocate for well-powered
randomized controlled trials to help elucidate these important
questions. n
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